CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today that it has signed an agreement with
purchasers for a private placement of its common stock and warrants for up
to $2.3 million in tranches, assuming no exercise of the warrants. The
company intends to use the net proceeds for working capital and general
corporate purposes. The first closing occurred on June 30, 2008, and
subsequent closings are subject to conditions in the agreement.
Under the terms of the agreement, Biopure is selling to accredited
investors up to 6,810,772 shares of its common stock and warrants to
acquire up to an additional 6,810,772 shares. The price for one share and
one warrant is $0.3377, and the exercise price of each warrant is $0.45.
The warrants have a term of five years, become exercisable six months after
the closing date, and are callable by Biopure after the initial exercise
date provided that the weighted average price of Biopure's common stock for
ten consecutive days is over $0.675. Biopure is obliged to file with the
U.S. Securities and Exchange Commission a resale registration statement
relating to the common stock to be issued in the transaction and the shares
of common stock to be issued upon the exercise of the warrants.
"We are pleased with the confidence private individuals have shown in
continuing to finance Biopure and our mission to bring Hemopure to market
in the U.S.," said Zafiris G. Zafirelis, CEO and President Biopure
Corporation.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals
called oxygen therapeutics that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. The Company is
developing Hemopure for other indications and is supporting the U.S. Navy's
government-funded efforts to develop a potential out-of-hospital trauma
indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer
-- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for
marketing by both the U.S. Food and Drug Administration and the European
Commission, is indicated for the treatment of anemia in dogs. Biopure has
sold approximately 200,000 units of Oxyglobin since its launch.
Statements in this release that are not strictly historical are
forward-looking statements, including any statements implying that the
maximum amount that can be raised in the private placement will be raised,
that any clinical trial will be initiated and/or carried out to completion
or that study results will be as desired, and any statements that might
imply that Hemopure may receive marketing approval in any jurisdictions
other than South Africa or for a trauma indication anywhere. Actual results
and their timing may differ materially from those projected in these
forward-looking statements due to risks and uncertainties. These risks
include, without limitation, uncertainties regarding the company's
financial position, including its limited cash resources and need to raise
additional capital to pursue its business, unexpected costs and expenses,
delays and adverse determinations by regulatory authorities, unanticipated
problems with the product's commercial use, whether or not product related,
and with product distributors, sales agents or other third parties, delays
in clinical trials, and the other factors identified under the heading
"Risk Factors" in the Company's quarterly report on Form 10-Q filed on June
16, 2008, as amended on June 18, 2008, which can be accessed in the EDGAR
database at the U.S. Securities and Exchange Commission's (SEC) website,
http://www.sec.gov. The company undertakes no obligation to release
publicly the results of any revisions to these forward-looking statements
to reflect events or circumstances arising after the date hereof. A full
discussion of the company's operations and financial condition can be found
in the company's filings with the SEC.
Contact: Tiana Gorham
Biopure Corporation
(617) 234-6826
IR@biopure.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
http://www.prnewswire.com/comp/131224.html /
CONTACT:
Tiana Gorham of Biopure Corporation,
+1-617-234-6826, IR@biopure.com
|
